Zynerba Pharmaceuticals — Investor Presentation (June 2020)
48 slides from Zynerba Pharmaceuticals's investor presentation, Jun 2, 2020
Slide 1: Corporate Overview June 2, 2020
Corporate Overview June 2, 2020
Slide 2: Forward-Looking Statements
Forward - Looking Statements 2 © 2020 Zynerba Pharmaceuticals, Inc. All rights reserved. Zynerba and Zygel are trademarks of Zynerba Pharmaceuticals, Inc. All other trademarks and registered trademarks are property of their respective owners. trademarks are property of their respective owners. THE S
Slide 3: A Rare/Near-Rare Neuropsychiatric Company
Zynerba Pharmaceuticals (NASDAQ: ZYNE) 3 A Rare/Near - Rare Neuropsychiatric Company • Deep pipeline focused on high unmet medical needs; translating into multi - billion dollar market opportunity with Zygel ™(CBD gel) • Four clinical shots on goal: FXS, DEE, ASD, 22q • Positive results announced in
Slide 4: COVID-Preparedness
COVID - 19 Preparedness 4 • We believe we have made smart and actionable adjustments in response to COVID - 19: • These include remote site monitoring and remote visits using telemedicine where needed • Our approach is consistent with FDA’s Guidance on Conduct of Clinical Trials of Medical Products
Slide 5: Deep Clinical Pipeline
Deep Clinical Pipeline 5 *Orphan Drug Designation Zygel Cannabidiol Gel Expected Milestones Topline pivotal data in late June 2020 Results of discussions with FDA on clinical path forward in 3Q2020 Topline Phase 2 data in 3Q2 020 Discussions with FDA in 1H2020 to define clinical path forward
Slide 6: Zygel (ZYN002) Cannabidiol Gel
Neuropsych Indications Differentiated F ormulation delivers CBD through the epidermis and into the circulatory system Zygel (ZYN002) Cannabidiol (CBD) Gel 6 Unique MOA First & only patent - protected, permeation - enhanced, pharmaceutically - produced CBD gel Transdermal CBD modulates multiple recep
Slide 7: Fragile X Syndrome (FXS)
Fragile X Syndrome (FXS) 7
Slide 8: Fragile X Syndrome (FXS) Overview
Fragile X Syndrome (FXS) Overview 8 • Rare genetic developmental disability • L eading known cause of both inherited intellectual disability and autism spectrum disorder • Symptoms linked to deficiencies in the endocannabinoid (EC) system • System of neurotransmitters regulating emotional responses,
Slide 9: FAB-C Open Label Phase 2 Trial Design
Day 1 to Week 6 Week 7 to 12 Up to 24 months FAB - C Open Label Phase 2 Trial Design 9 Treatment of F ragile X Syndrome A nxiety and B ehavioral C hallenges with CBD Titration Maintenance Screening Open label extension D osing initiated at 50 mg Zygel daily; may be titrated up to 250 mg Zygel daily
Slide 10: Data From Three Month FAB-C Phase 2 Trial
Data From Three Month FAB - C Phase 2 Trial 10 0 10 20 30 40 50 60 70 Social Avoidance Irritability Socially Unresponsive / Lethargic Inappropriate Speech Stereotypy Hyperactivity Month 3 (n=18) Baseline: 18.2 Baseline: 14.5 Baseline: 8.7 Baseline: 5.1 Baseline: 7.9 Baseline: 6.1 41.8% 52.9% 54.9% 3
Slide 11: Sustained Improvements in FXS Behavioral Symptoms Through Two Years
11 0 10 20 30 40 50 60 70 80 90 Social Avoidance Irritability Socially Unresponsive Hyperactivity Stereotypy Inappropriate Speech Month 3 (n=12) Month 12 (n=9) Month 24 (n=10) 57.9* 51.1* 65.7* 36.7* 60.8* 56.5* *P ≤ 0.05 Mean % Improvement from Baseline 77.2* 59.2* 72.2* 40.4* 64.9* 56.5* Improveme
Slide 12: ≥25% Responder Analyses
FAB - C Open Label Phase 2 Trial 12 ≥25% Responder Analyses for Patients Who Entered Period 2 Data reported at the 2020 American Academy of Neurology (AAN) Science Highlights Virtual Session Proportion of Patients with a ≥25% Improvement from Baseline ABC - C FXS Subscales 0 10 20 30 40 50 60 70 80
Slide 13: ≥50% Responder Analyses
FAB - C Open Label Phase 2 Trial 13 ≥50% Responder Analyses for Patients Who Entered Period 2 Data reported at the 2020 American Academy of Neurology (AAN) Science Highlights Virtual Session Proportion of Patients with a ≥50% Improvement from Baseline ABC - C FXS Subscales 0 10 20 30 40 50 60 70 80
Slide 14: Zygel Safety Summary Through 24 Months
FAB - C Open Label Phase 2 Trial 14 Zygel Safety Summary Through 24 Months • Well tolerated, consistent with previously reported data • No drug - related SAEs • 66 treatment - emergent adverse events (TEAE; all events, whether unrelated or related to study drug) reported in 19 patients • All were ei
Slide 15: Third Party Data Suggest Placebo Rate
Third Party Data* Suggest PBO Rate of 10 to 18 Percent 15 0 10 20 30 40 50 60 Zygel 0 10 20 30 40 50 Zygel 0 10 20 30 40 50 60 Zygel 0 10 20 30 40 50 Zygel 0 10 20 30 40 50 60 Zygel 0 10 20 30 40 Zygel Socially Unresponsive / Lethargic Does not pay attention Inappropriate Speech Repeats words / phra
Slide 16: CONNECT-FX: A Pivotal Trial In FXS
CONNECT - FX: A Pivotal Trial In FXS 16 C linical study O f Ca NN abidiol (CBD) in Childr E n and Adoles C en T s with F ragile X (CONNECT - FX) Zygel 250 mg daily 500 mg daily (weight - based dose) Placebo Mirrors Zygel administration Patients randomized (1:1) to receive either Zygel or placebo Tre
Slide 17: CONNECT-FX: A Pivotal Trial In FXS
CONNECT - FX: A Pivotal Trial In FXS 17 • Primary endpoint: • Change from baseline to end of treatment in ABC - C FXS Social Avoidance subscale • Key secondary endpoints: • Change from baseline to end of the treatment in • ABC - C FXS Irritability subscale score • ABC - C FXS Socially Unresponsive/L
Slide 18: CONNECT-FX Demographics
CONNECT - FX Demographics 18 Patients n Randomization: Enrollment complete 212 Number of male patients 159 (75%) Mean age at randomization in study 9.7 years Completed 14 - week Tx period (as of 5/8/2020) 188 Percent of completed patients enrolling in CONNECT - FX OLE 96%
Slide 19: Baseline Behavior Severity: CONNECT-FX vs Ph2 FAB-C
Baseline Behavior Severity: CONNECT - FX vs Ph2 FAB - C 19 Prospective inclusion criteria expected to provide a more severely impacted population which we believe should enhance ability to demonstrate a strong signal of activity and minimize response variability Note : Higher baseline scores denote
Slide 20: CONNECT-FX
CONNECT - FX 20 • W ith positive results in pivotal trial, Zynerba intends to request a meeting with the FDA to : • Determine acceptability of data as basis for NDA filing by YE 2020 • Seek advice on marketing authorization preparation • Potential approval by mid - year 2021 • Zynerba believes the i
Slide 21: Improvements in Behavior May Provide a Read-Through to Other Zygel Studies
21 • Presented data at SSBP* showing constellation of shared socio - behavioral symptoms in ASD, FXS, and 22q11.2DS • These include anxiety leading to: • Isolation and social avoidant behaviors • Irritability • Attention deficits • Poor communication Improvements in Behavior May Provide a Read - Thr
Slide 22: Autism Spectrum Disorder (ASD) in children and adolescents
22 Autism Spectrum Disorder (ASD) in c hildren and adolescents
Slide 23: ASD in Pediatrics Overview
ASD in Pediatrics Overview 23 • Near - rare disorder affecting ~ 1MM pediatric and adolescent pts • DSM - 5 diagnosis • Symptoms include • Irritability • Anxiety • Restricted, repetitive patterns of behavior • Impairments in social communication • Deficits in verbal and non - verbal communication •
Slide 24: Developing Zygel in ASD
Developing Zygel in ASD 24 • Newer studies suggest ASD is linked to disruption in the EC system • Altered anandamide signaling may contribute to ASD - related social and communication impairments • EC system modulates many cellular functions and molecular pathways altered in ASD: imbalanced GABAergi
Slide 25: BRIGHT Phase 2 Trial in ASD
BRIGHT Phase 2 Trial in ASD 25 Open - La B el Tole R ab I lity and Efficacy Study of ZYN002 Administered as a Transdermal G el to C H ildren and Adolescen T s with Autism Spectrum Disorder 37 patients enrolled Three through 17 years of age Screening Zygel 14 Weeks Weight based dosing: 14 Weeks: COMP
Slide 26: Baseline Patient Population: BRIGHT
Baseline Patient Population: BRIGHT Patients enrolled N = 37 Included in safety analysis 37 Included in efficacy analyses 36* Discontinuations 9 Patients completing 14 - week trial 28 BRIGHT Trial Patient Populations 26 * One patient was lost to follow up and did not have post - dosing efficacy asse
Slide 27: Baseline Patient Demographics
Baseline Patient Demographics Patients enrolled, n 37 Age, years Mean (range ) 9.2 (3 - 16) Sex, n (%) Male Female 34 (91.9) 3 (8.1) Race, % White Asian Native Hawaiian or othe r Pacific Island Other 70.3 8.1 2.7 18.9 Time to diagnosis, years 5.4 Underlying medication, % Subjects entering with ≥1 un
Slide 28: Percent Improvement in ABC-C Subscale Scores at Week 14
Percent Improvement in ABC - C Subscale Scores at Week 14 vs. Baseline 28 0 5 10 15 20 25 30 35 40 45 Irritability Inappropriate Speech Stereotypy Social withdrawal Hyperactivity Baseline: 30.3 Baseline: 12.3 Baseline: 7.4 Baseline: 37.0 Baseline: 25.1 39.1% 42.5% 35.6% 36.4% 42.6% Mean % Improvemen
Slide 29: ABC-C Responses Supported by Other Efficacy Assessments
Results of other efficacy assessments support the results demonstrated in the ABC - C, including: • Parent Rated Anxiety Scale - Autism Spectrum Disorder (PRAS - ASD): • M ean improvement of 46% at week 14 from baseline (p<0.0001) • Clinical Global Impression - Improvement (CGI - I ) • 57 % of patie
Slide 30: Strong Safety and Tolerability Profile in BRIGHT Trial in ASD
• W ell tolerated; consistent with previously released data • Fewer than half of patients experienced an AE; most were mild and transient • Only 14% of patients experienced a treatment - related AE • All application site - related • No severe or serious adverse events reported during the study. 30 S
Slide 31: 22q11.2 Deletion Syndrome (22q)
22q11.2 Deletion Syndrome ( 22q) 31
Slide 32: 22q Overview
22q Overview 32 • Most common contiguous gene deletion syndrome • Rare disorder: ~81K patients in US • Midline condition with abnormalities affecting palate, face, heart and other organs; surgically corrected in infancy • Neuropsychiatric illnesses (anxiety disorders, ASD) and learning disabilities
Slide 33: 22q Patient Management
22q Patient Management 33 • Two primary stages of 22q patient management: • During infancy, doctors address acute physical concerns, such as anomalies of heart and palate, with surgery • Once the physical concerns are stabilized, focus shifts to managing neuropsychiatric symptoms, such as anxiety an
Slide 34: Developing Zygel in 22q
Developing Zygel in 22q 34 • CBD may treat neuropsychiatric symptoms in 22q due to activity as: • Modulator of endocannabinoid system • Agonist at serotonin 1A receptors • Antagonist at GPR55 receptors • Early control of anxiety may delay the development of psychosis • Phase 2 study underway in pedi
Slide 35: INSPIRE Phase 2 Trial in 22q
INSPIRE Phase 2 Trial in 22q 35 Target: 20 patients Six through 17 years of age Screening Zygel 14 Weeks Weight based dosing: 14 Weeks 250 mg to 500 mg daily E fficacy assessments (week 14 vs baseline) include: • Aberrant Behavior Checklist - Community ( ABC - C) • Anxiety , Depression and Mood Scal
Slide 36: DEE Developmental and Epileptic Encephalopathies
DEE Developmental and Epileptic Encephalopathies 36
Slide 37: DEE Patients are Medically Fragile
DEE Patients are Medically Fragile 37 • G roup of rare / ultra rare childhood - onset epilepsies with impaired or regressed developmental progress • Cognitive impairment, psychiatric problems, and behavioral disturbances are phenotypic • Medically fragile population • Comorbidities include cerebral
Slide 38: BELIEVE Phase 2 Trial in DEE
BELIEVE Phase 2 Trial in DEE 38 Open La B el Study to Assess the Safety and E fficacy of ZYN002 Administered as a Transderma L Gel to Ch I ldren and Adol E scents with De V elopmental and E pileptic Encephalopathy 48 patients enrolled Three through 17 years of age Screening Maintenance 22 Weeks Titr
Slide 39: BELIEVE: Clinically Meaningful Seizure Reductions Sustained Through Six Months
39 BELIEVE: Clinically Meaningful Seizure Reductions from Baseline and Sustained through Six Months in DEE 0 10 20 30 40 50 60 70 Month 1 Month 2 Month 3 Month 4 Month 5 Month 6 Median Percent Reduction from Baseline, FIAS and CS N=33 N=33 N=33 N=32 N=32 N=29 16 44 44 47 58 51 Median Percent Reducti
Slide 40: BELIEVE: Percentage of Patients with ≥35% and ≥50% Reduction
BELIEVE: Percentage of Patients with ≥35% and ≥50% Reduction in FIAS and TCS 40 Data reported at the 2020 American Academy of Neurology (AAN) Science Highlights Virtual Session ≥35 % and ≥50 % Reduction in FIAS and TCS by Time Point , mITT Population With FIAS and/or TCS at Baseline (n = 33)
Slide 41: BELIEVE Safety: Well Tolerated in Six Month Trial
41 • All events in six month period, whether unrelated or related to study, drug reported as adverse events (AEs) (e.g.: influenza, runny nose, ingrown toenail, scrapes, etc.) • As a result and as anticipated, most patients experienced an AE • Most were mild and transient • Only one patient disconti
Slide 42: BELIEVE: Qualitative Assessments of Behavioral and Cognitive Improvements
42 BELIEVE: Qualitative Assessments of Behavioral and Cognitive Improvements • Epilepsy and Learning Disabilities Quality of Life (ELDQOL) scale • Statistically significant reductions from baseline in subscale scores for seizure severity, behavior, and mood observed at month 6 (p<0.01) • Qualitative
Slide 43: BELIEVE: Qualitative Assessments of Behavioral and Cognitive Improvements
43 BELIEVE: Qualitative Assessments of Behavioral and Cognitive Improvements • Good Day/Bad Day comparing baseline to month six: • “Good day” and “fantastic day” reports increased from 52% to 70% • “Terrible day” and “bad day” reports decreased from 12% to 4% Data reported at the 2020 American Acade
Slide 44: Compelling Results Suggest a Pathway to Pivotal Trials
44 • Zynerba engaging with FDA on next clinical steps • Efficacy results: • Clinically meaningful reductions in seizures beginning in month two and sustained through six months • Suggest improvements on important behavioral symptoms • Safety results: • Zygel was well tolerated • Consistent with prev
Slide 45: Planned Approach to FDA
45 Syndromes and encephalopathies Dravet LGS West Early myoclonioc epilepsy Hypoxic - ischemic e nceph . S eizure type Focal Impaired Awareness Bilateral Tonic Clonic Generalized Tonic Clonic Focal aware Absence Convulsive Other Seizure types Consciousness impairing seizures Doose Ohtahara Landau -
Slide 46: Financial Strength
Financial Strength 46 • Clean balance sheet • No debt, 25.0M shares outstanding (as of May 7, 2020) • Cash and cash equivalent position of $60.6M as of March 31, 2020 • Cash runway expected to be sufficient to fund operations and capital requirements into the second half of 2021 • Beyond the expecte
Slide 47: Expected Clinical Milestones in 2020
Expected Clinical Milestones in 2020 47 FXS DEE Report pivotal CONNECT - FX topline results ASD 22q 1Q 2020 2Q 2020 Report Ph. 2 BRIGHT topline results Report Ph. 2 INSPIRE topline results 3Q 2020 4Q 2020 NDA submission Meet with FDA to discuss clinical path forward Results of FDA discussions on cli
Slide 48: Corporate Overview June 2, 2020
Corporate Overview June 2, 2020
Zynerba Pharmaceuticals — Investor Presentation (June 2020) on 6ix